文献速递神经创伤神经重症

住院期间金刚烷胺不改善重型创伤性脑损伤结局:一项11年倾向匹配回顾性分析

In-Hospital Amantadine Does Not Improve Outcomes After Severe Traumatic Brain Injury: An 11-Year Propensity-Matched Retrospective Analysis.
PubMed 文献 · World Neurosurg · 2023-06-17

该研究回顾2010至2021年本院收治的存活超过10天的重型创伤性脑损伤患者,比较接受金刚烷胺者与未接受者及倾向评分匹配对照组的结局。金刚烷胺组在死亡率、遵循指令恢复率、出院格拉斯哥昏迷量表严重评分比例上与匹配对照组无差异,但有利恢复比例更低、住院时间更长、恢复遵循指令时间更长。结论不支持早期使用金刚烷胺。

要点

  • 金刚烷胺组与匹配对照组死亡率86.67% vs 88.33%,无显著差异(P=0.783)。
  • 金刚烷胺组有利恢复(出院GOS-E 5-8)比例14.53% vs 16.67%,P<0.001。
  • 金刚烷胺组住院时间40.5天 vs 21.0天,恢复遵循指令时间11.5天 vs 6.0天。

核心结论

  • 研究结果不支持重型创伤性脑损伤后早期使用金刚烷胺。
  • 需要更大规模的住院患者随机试验进一步研究金刚烷胺治疗重型创伤性脑损伤。

研究设计与样本

  • 回顾性分析2010至2021年本院收治的存活超过10天的重型创伤性脑损伤患者。
  • 60例接受金刚烷胺,344例未接受,并与倾向评分匹配的非金刚烷胺组比较。

主要发现

  • 金刚烷胺组与倾向评分匹配非金刚烷胺组死亡率86.67% vs 88.33%,P=0.783。
  • 金刚烷胺组遵循指令恢复率73.33% vs 76.67%,P=0.673。
  • 金刚烷胺组出院格拉斯哥昏迷量表严重评分(3-8分)比例11.11% vs 12.28%,P=0.434。
  • 金刚烷胺组有利恢复(出院GOS-E 5-8分)比例14.53% vs 16.67%,P<0.001。
  • 金刚烷胺组住院时间40.5天 vs 21.0天,恢复遵循指令时间11.5天 vs 6.0天,P=0.011;两组不良事件无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Disruption of dopamine neurotransmission is associated with functional impairment after severe traumatic brain injury (sTBI). This has prompted the study of dopamine agonists, such as amantadine, to assist recovery of consciousness. Randomized trials have mostly addressed the posthospital setting, with inconsistent findings. Therefore, we evaluated the efficacy of early amantadine administration on recovery of consciousness after sTBI. METHODS: We searched the medical records of all patients with sTBI admitted to our hospital between 2010 and 2021 who survived 10 days postinjury. We identified all patients receiving amantadine and compared them with all patients not receiving amantadine and a propensity score-matched nonamantadine group. Primary outcome measures included discharge Glasgow Coma Scale, Glasgow Outcome Scale-Extended score, length of stay, mortality, recovery of command-following (CF), and days to CF. RESULTS: In our study population, 60 patients received amantadine and 344 did not. Compared with the propensity score-matched nonamantadine group, the amantadine group had no difference in mortality (86.67% vs. 88.33%, P = 0.783), rates of CF (73.33% vs. 76.67%, P = 0.673), or percentage of patients with severe (3-8) discharge Glasgow Coma Scale scores (11.11% vs. 12.28%, P = 0.434). In addition, the amantadine group was less likely to have a favorable recovery (discharge Glasgow Outcome Scale-Extended score 5-8) (14.53% vs. 16.67%, P < 0.001), had a longer length of stay (40.5 vs. 21.0 days, P < 0.001), and had a longer time to CF (11.5 vs. 6.0 days, P = 0.011). No difference in adverse events existed between groups. CONCLUSIONS: Our findings do not support the early administration of amantadine for sTBI. Larger inpatient randomized trials are necessary to further investigate amantadine treatment for sTBI.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Passman JN, Cleri NA, Saadon JR, et al. In-Hospital Amantadine Does Not Improve Outcomes After Severe Traumatic Brain Injury: An 11-Year Propensity-Matched Retrospective Analysis. World Neurosurg. 2023. PMID: 37331473. doi:10.1016/j.wneu.2023.06.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。